The effects of lilalucopeptide combined with alendronate on bone mineral density and serum BGP, s-ctx and BAP levels in patients with type 2 diabetes mellitus and osteoporosis.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015107

Enrollment

Unknown

Registered

2018-03-07

Start date

2018-04-01

Completion date

Unknown

Last updated

2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

The experimental group:Lilalupeptide combined with alendronate sodium therapy.

The control group:Novorapid 30 combined with alendronate sodium.

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) the world health organization's diabetes diagnosis standard in 1999 [5], that is, fasting blood glucose is greater than 7. 0 mmol/L; Glucose tolerance test 2 h blood glucose was greater than 11.1 mmol/L; (2) the world health organization (who) developed the diagnosis standard for osteoporosis, that is, the bone density is less than 2.5 standard deviations (T = -2.5); (3) no glucocorticoid was used within half a year, and no effect on bone metabolism drugs was used within 1 year, and women had natural menopause for more than 5 years.

Exclusion criteria

Exclusion criteria: Not in accordance with the above situation.

Design outcomes

Primary

Measure	Time frame
serum BAP;	—

Countries

China

Contacts

Public ContactWang Xiaohui

Gansu Province Hospital of TCM

997869467@qq.com+86 13893390965

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026